Literature DB >> 10469891

An overview of cyclophosphamide development and clinical applications.

O M Colvin1.   

Abstract

In this overview of the pharmacology of the anticancer drug cyclophosphamide, a brief history of the development of this drug from the general class of nitrogen mustards is provided. The antitumor activity of cyclophosphamide and its isomer ifosfamide is discussed through considerations of metabolism, resistance, detoxification, and DNA cross-linking. Clinical uses in general chemotherapy, bone marrow transplantation and immunosuppression are presented. A review with 73 references.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10469891

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  48 in total

1.  Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.

Authors:  Mariana Malvicini; Mariana Ingolotti; Flavia Piccioni; Mariana Garcia; Juan Bayo; Catalina Atorrasagasti; Laura Alaniz; Jorge B Aquino; Jaime A Espinoza; Manuel Gidekel; O Graciela Scharovsky; Pablo Matar; Guillermo Mazzolini
Journal:  Mol Oncol       Date:  2011-04-05       Impact factor: 6.603

2.  Epigenetic programming in the preimplantation rat embryo is disrupted by chronic paternal cyclophosphamide exposure.

Authors:  Tara S Barton; Bernard Robaire; Barbara F Hales
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

Review 3.  Impact of environmental exposures on ovarian function and role of xenobiotic metabolism during ovotoxicity.

Authors:  Poulomi Bhattacharya; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-13       Impact factor: 4.219

4.  Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis.

Authors:  Melanie S Joy; Mary La; Jinzhao Wang; Arlene S Bridges; Yichun Hu; Susan L Hogan; Reginald F Frye; Joyce Blaisdell; Joyce A Goldstein; Mary Anne Dooley; Kim L R Brouwer; Ronald J Falk
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

5.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

6.  Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.

Authors:  Francis M Hughes; Nivardo P Vivar; James G Kennis; Jeffery D Pratt-Thomas; Danielle W Lowe; Brooke E Shaner; Paul J Nietert; Laura S Spruill; J Todd Purves
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-27

Review 7.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

8.  Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy.

Authors:  Eniko Bodó; Desmond J Tobin; York Kamenisch; Tamás Bíró; Mark Berneburg; Wolfgang Funk; Ralf Paus
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

9.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

10.  Effects of cell cycle inhibitors on tau phosphorylation in N2aTau3R cells.

Authors:  Concepcion Conejero-Goldberg; Kirk Townsend; Peter Davies
Journal:  J Mol Neurosci       Date:  2008-02-16       Impact factor: 3.444
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.